Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Sarcoma, Kaposi 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1AIDS-related Kaposi sarcoma 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Interleukin-12 × Dermatologic × Clear all
NCT01457131 2019-01-08

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled
DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00026143 2013-06-05

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡